For limited high grade<unk>  the typical treatment is chemotherapy and a targeted drug, followed by radiotherapy. While advanced high grade<unk>  patients receive similar treatments, the duration is extended. For advanced diffuse large B cell<unk>  the standard therapy for patients with DLBCL is the combination use of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). While this commonly used regimen results in 60-70 percent of patients with DLBCL to be cured of disease there is also a group of patients that relapse and do not respond well to R-CHOP. For these patients the current treatment strategies are insufficient in treating their cancer. In addition to this, alternative treatments continue to be research due to the highly toxic nature of R-CHOP. In contrast to mature B-cell neoplasms, therapeutic advances in peripheral T-cell<unk>  have generally lagged behind, particularly with regard to the introduction of immune therapies, which have impacted significantly and favorably on the prognosis of<unk>  B cell<unk> s such as diffuse large B-cell<unk> . As such, it remains a heterogeneous entity with a generally unfavorable prognosis.
Aggressive lymphoma
Indolent lymphoma
AIDS-related lymphoma
Gray zone lymphoma
Hodgkin lymphoma
Non-Hodgkin lymphoma
Mixed-cell lymphoma
Follicular lymphoma